: Amira Pharmaceuticals :

	BRADLEY BOLZON, Ph.D., Versant Ventures Acting Chairman Brad Bolzon brings more than 13 years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with Roche. Under his leadership, Roche’s Pharmaceuticals Division established alliances with over 75 biotech companies worldwide and significantly strengthened the company’s product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, business development, clinical research and regulatory affairs. Brad currently serves as a board member for Amira Pharmaceuticals, Antipodean Pharmaceuticals, Sentient Pharmaceuticals, Metabolex, Speedel and is Chairman of the Board of Synosia Therapeutics. He is also Chairman of EuroVentures, a wholly-owned start-up incubator of Versant Ventures. Brad received a Ph.D. and M.S. degrees in pharmacology from the University of Toronto and conducted his post-doctoral research training at the Ottawa Heart Institute in Ottawa, Canada. TOP
	ROBERT BALTERA, JR., M.B.A. Amira Pharmaceuticals Robert Baltera is a seasoned pharmaceutical industry executive, who acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. Before becoming Amira’s CEO, Bob held a number of senior management positions at Amgen, the last being vice president of corporate and contract manufacturing. A scientist by training, Bob joined Amgen at the beginning of his career as a research associate but quickly moved to the operations side of the business, working in finance, product development and commercial operations. He successfully used his collective experience to serve as team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen. Bob has a master’s of business administration from the Anderson School at UCLA and earned his bachelor’s degree in microbiology and a master’s degree in genetics from The Pennsylvania State University. TOP
	DENNIS M. FENTON, Ph.D. Independent Member Dennis Fenton has over 30 years of pharmaceutical and biotechnology experience, including over 25 years at Amgen. During his tenure at Amgen, Dennis held numerous positions at Amgen including executive roles in process development, manufacturing, sales and marketing, and research and development. Most recently, Dennis was Executive Vice President responsible for worldwide operations, manufacturing, process development and quality. Under Dennis’ leadership, Amgen established manufacturing operations in California, Colorado, Puerto Rico and Rhode Island. Dennis also serves on the board of trustees of Rutgers University and the Keck Graduate Institute. He has a Ph.D. in Microbiology from Rutgers University. TOP
	STEPHEN W. KALDOR, Ph.D. Independent Member Steve Kaldor, Ph.D. is currently President and Chief Executive Officer of Ambrx, a San Diego-based biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Prior to this role, Dr. Kaldor served as President and CSO of Takeda San Diego Inc., the US Discovery Research Center for Takeda Pharmaceuticals. He instigated and led the March 2005 $270MM acquisition of Syrrx Inc. by Takeda that resulted in the creation of Takeda San Diego. Dr. Kaldor ran Syrrx, a privately held, structure-based drug discovery company, as its President and CSO from 2003 to 2005. Prior to joining Syrrx, Dr. Kaldor gained over 12 years of drug discovery and development experience at Eli Lilly and Company, as both a researcher and Director with line management responsibility for groups of up to 270 people. He received his formal education in organic chemistry at Harvard University, (Ph.D., 1989) and Columbia University, (B.S., 1984). Dr. Kaldor is the co-inventor of multiple compounds that have advanced into the clinic including Viracept®, a marketed HIV protease inhibitor. TOP
	KEVIN KINSELLA, B.S., M.A. Avalon Ventures Kevin Kinsella founded Avalon Ventures in 1983 and has since helped to form, finance and develop more than 60 early-stage companies, including: Athena Neurosciences (acquired by ELAN (ELN)); Onyx Pharmaceuticals (ONXX); Sequana Therapeutics (SQNA) [merged with Arris to form AXYS Pharmaceuticals (AXPH) acquired by Celera Genomics (CRA)]; Vertex Pharmaceuticals (VRTX); Synaptics, Inc. (SYNA); Vocera Communications; and Sytera Inc. (acquired by Sirion). Kevin was the founding chairman of Athena, Aurora, Landmark, NeoRx, Onyx, Synaptics, Vertex, X-Ceptor and Sequana. He was chairman of the investment committee of Poland Partners and INNOVA 98, respectively a $62.5 million and a $125 million fund investing in Central Europe. Kevin currently serves as a director on the Boards of Ambit, Amira Pharmaceuticals, Anaptys, InCode and Sirion and is a Board observer at BioVex and Acceleron. Prior to founding Avalon, Kevin worked for Solar Turbines International (Caterpillar Tractor) where he was in charge of all international joint-ventures, barter and counter-trade; served as an advisor to the Peruvian government in National Nutrition Planning; taught algebra at the American High School in Beirut, Lebanon, and served as guest op-ed columnist for the Boston Herald American. He is a graduate of the Massachusetts Institute of Technology with a B.S. degree in management and holds a M.A. degree in international relations from the Johns Hopkins School of Advanced International Studies. Outside Avalon, Kevin is a member of the Circumnavigators Club, an elite group of explorers; Vice President of the Board of Trustees of the San Diego Museum of Art; producer of the Tony Award winning hit Broadway musical, Jersey Boys; a member of the Council on Foreign Relations and a member of the League of American Theaters and Producers. He is the holder of two U.S. patents on anti-diabetic compounds. TOP
	HEATH LUKATCH, Ph.D. Novo A/S Heath has extensive experience investing in healthcare. He opened Novo Ventures’ San Francisco office in 2006, was a founding partner of SightLine Partners, and Managing Director and Head of Biotechnology Venture Investments at Piper Jaffray Ventures. Heath has invested in multiple biotechnology and medical device companies and currently serves as a director at Synosia, Inogen and NeuroTherapeutics. Prior to his involvement in venture capital, Heath worked as a strategy consultant with McKinsey & Company, serving a range of large and small healthcare clients. Previously, he was founder and CEO of AutoMate Scientific, a San Francisco-based company specializing in biotechnology instrumentation. He has also worked as a bench scientist at Chiron, Cetus and Roche Bioscience in molecular biology, protein chemistry and electrophysiology. Heath earned his Ph.D. in neuroscience from Stanford University and his undergraduate degree with high honors in biochemistry from the University of California at Berkeley. TOP
	PEPPI PRASIT, Ph.D. Amira Pharmaceuticals Peppi Prasit has more than 20 years of experience in pharmaceutical research and management, most recently serving in various positions with Merck. These roles included head of chemistry at the company’s San Diego facility. While at Merck, Peppi was the lead scientist responsible for Vioxx® and Arcoxia® and was involved in the optimization program that led to Singulair®. During his career, Peppi has led and/or contributed to research resulting in more than 65 published papers exploring various elements of drug discovery. Among other numerous research achievements, Peppi was part of a group that discovered potent, orally active CysLT1 antagonists, Cathepsin K inhibitors and FLAP inhibitor that went to clinic. He holds more than 30 granted patents. Peppi received his Ph.D. in organic chemistry from Victoria University of Wellington in New Zealand and served as a post-doctoral fellow in organic and organometallic chemistry at Princeton University in New Jersey. TOP
	JAMES TANANBAUM, M.D., M.B.A. Prospect Venture Partners Jim Tananbaum is managing director and co-founder of Prospect Venture Partners II and III, a dedicated life science fund with over $1 billion in capital under management. Jim has over a decade’s experience in the biotech and pharmaceutical sector. During his time with Prospect, he has helped found and lead financing for many biotechnology, pharmaceutical and healthcare service companies, including Cogentus, Infinity Pharmaceuticals, Jazz Pharmaceuticals, Novavax, Pathworks, RoxRo Pharma, Vanda Pharmaceuticals and Vitae Pharmaceuticals. Previously, as a partner at Sierra Ventures, he led investments in Amerigroup, Healtheon, Intensiva HealthCare Corporation and NovaMed EyeCare Management. From 1991 to 1993, Jim was a senior product manager at Merck & Company, where he was part of the team responsible for repositioning Prilosec®. Jim was also the founder of two successful biotechnology companies: GelTex, which he founded in 1991 and which was bought for $1.6b by Genzyme, and Theravance, founded in 1997 where as CEO for its first three years, he developed the company to over 200 employees. Jim is a member of the Young Presidents' Organization and Chapter Chair Golden Gate Chapter and a member of the Harvard/MIT Health Sciences and Technology Visiting Committee. He received his undergraduate degree and B.S.E.E. from Yale University, and his M.D. and M.B.A. from Harvard. TOP